We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byCorey Hunter
Modified over 2 years ago
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle- Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, and Hartmut Döhner Blood Volume 123(21):3247-3254 May 22, 2014 ©2014 by American Society of Hematology
Incidence and distribution of gene mutations, genomic aberrations, and IGHV status for the patients with all markers available (n = 573). Stephan Stilgenbauer et al. Blood 2014;123:3247-3254 ©2014 by American Society of Hematology
Kaplan-Meier estimates. Stephan Stilgenbauer et al. Blood 2014;123:3247-3254 ©2014 by American Society of Hematology
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG) by Peter Paschka,
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.
Should Chlorambucil Be Used with Obinutuzumab in Untreated CLL? Answer: YES! Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma Translational.
The genetic basis of myelodysplasia and its clinical relevance
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease by Françoise Bernaudin, Gérard Socie, Mathieu Kuentz,
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.
1 EBMT Lymphoma Working Party 11th Educational Course Treatment of Malignant Lymphoma: State of the Art and the Role of Stem Cell Transplantation
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations by Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie.
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.
© 2017 SlidePlayer.com Inc. All rights reserved.